US 10,772,929 B2Granted

Use of peptide compounds in treating acute pancreatitis

AssigneeShenzhen HighTide Biopharmaceutical, Ltd.

InventorsLiping Liu, Ru Bai

Life of this patent

Estimating the term…

Abstract

Method of use of peptides and their analogs in the treatment of acute pancreatitis are described. The disclosed peptides and analogs can significantly lower the elevated blood amylase and lipase levels caused by acute pancreatitis, reduce the degree of injury observed in pancreatic histopathology caused by pancreatitis, and significantly lower the mortality rate of acute pancreatitis.

Claims6

Dependent claims

A method for treating acute pancreatitis comprising administering to a patient having acute pancreatitis a pharmaceutical composition comprising an INGAP-PP peptide selected from:

TABLE 2
1
H-IGLHDPSHGTLPNGS-OH
6
H-IGLHAPSHGTLPNGS-OH
7
H-IGLHDPSHGTLPAGS-OH
8
H-IGLHAPSHGTLPAGS-OH
9
H-IGLHDPSHGTLPAGSK-OH
10
H-IGLHDPSHGTLP(Aib)GS-OH
11
H-IGLHDPSHGTLP(N-methyl-L-
Alanine)GS-OH
12
Ac-IGLHDPSHGTLPAGS-OH
13
H-(D-Isoleucine)GLHDPSHGTLPAGS-OH
14
H-(L-NorValine)GLHDPSHGTLPAGS-OH
15
H-(L-NorLeucine)GLHDPSHGTLPAGS-OH
16
Ac-IGLHDPSHGTLPNGS-OH
17
H-(D-Isoleucine)GLHDPSHGTLPNGS-OH
18
H-IGLHDPSHGTEPNGS-OH
19
H-IGLHDPSQGTLPNGS-OH
20
H-IGLHDPTHGTLPNGS-OH
21
H-IGLHDPSHGTLPNGE-OH
22
H-IGLHDPSHGTLPNGK-OH
23
H-IGLHDPSHGTLPAGK-OH
24
H-IGLHDPSHGTEPAGS-OH
25
H-IGLHDPSQGTLPAGS-OH
26
H-IGLHDPTHGTLPAGS-OH
27
H-IGLHDPSHGTLPAGE-OH
28
H-IGLHDPSHGTLPAG-NH2
29
Ac-IGLHDPSHGTLPAGS-NH2
30
Ac-IGLHDPSHGTLPAG-NH2
31
Ac-IGLHDPSHGTLPNGS-NH2
32
H-IGLHDPSHGTLPNGS-NH2
33
H-IGLHDPSHGTLPNGSC-OH
34
Ac-IGLHDPSHGTLPNGSC-OH
35
H-IGLHDPSHGTLPNGSC-NH2
36
Ac-IGLHDPSHGTLPNGSC-NH2
37
H-IGLHDPSHGTLPNGC-OH
38
Ac-IGLHDPSHGTLPNGC-OH
39
H-IGLHDPSHGTLPNGC-NH2
40
Ac-IGLHDPSHGTLPNGC-NH2
41
H-IGLHDPSHGTLPAGS-NH2
42
H-IGLHDPSHGTLPAGSC-OH
43
Ac-IGLHDPSHGTLPAGSC-OH
44
H-IGLHDPSHGTLPAGSC-NH2
45
Ac-IGLHDPSHGTLPAGSC-NH2
46
H-IGLHDPSHGTLPAGC-OH
47
Ac-IGLHDPSHGTLPAGC-OH
48
H-IGLHDPSHGTLPAGC-NH2
49
Ac-IGLHDPSHGTLPAGC-NH2
73
IGLHDPSHGTLPAG
74
IGLHDPSHGTLPNG
75
Ac-IGLHDPSHGTLPNG
76
IGLHDPSHGTLPNG-NH2
77
Ac-IGLHDPSHGTLPNG-NH2
78
H-IGLHDPSHGTLPQGS-OH
79
H-IGLHDPSHGTLPDGS-OH
80
H-IGLHDPSHGTLPEGS-OH
81
H-IGLHEPSHGTLPNGS-OH
82
H-IGLHQPSHGTLPNGS-OH
83
H-IGLHNPSHGTLPNGS-OH
84
H-IGLHEPSHGTLPAGS-OH
85
H-IGLHQPSHGTLPAGS-OH
86
H-IGLHNPSHGTLPAGS-OH
87
H-IGLHDPSHGTLPQGSC-OH
88
H-IGLHDPSHGTLPDGSC-OH
89
H-IGLHDPSHGTLPEGSC-OH
90
H-IGLHEPSHGTLPNGSC-OH
91
H-IGLHQPSHGTLPNGSC-OH
92
H-IGLHNPSHGTLPNGSC-OH
93
H-IGLHDPSHGTLPQG-OH
94
H-IGLHDPSHGTLPDG-OH
95
H-IGLHDPSHGTLPEG-OH
96
H-IGLHEPSHGTLPNG-OH
97
H-IGLHQPSHGTLPNG-OH
98
H-IGLHNPSHGTLPNG-OH
99
H-IGLHEPSHGTLPAG-OH
100
H-IGLHQPSHGTLPAG-OH
101
H-IGLHNPSHGTLPAG-OH
102
H-IGLHDPSHGTLPQGE-OH
103
H-IGLHDPSHGTLPDGE-OH
104
H-IGLHDPSHGTLPEGE-OH
105
H-IGLHEPSHGTLPNGE-OH
106
H-IGLHQPSHGTLPNGE-OH
107
H-IGLHNPSHGTLPNGE-OH
108
H-IGLHEPSHGTLPAGE-OH
109
H-IGLHQPSHGTLPAGE-OH
110
H-IGLHNPSHGTLPAGE-OH.

165 more elements

A method for treating acute pancreatitis by lowering the levels of amylase and lipase in the blood of a patient having acute pancreatitis comprising administering the patient a pharmaceutical composition comprising an INGAP-PP peptide selected from:

TABLE 2
1
H-IGLHDPSHGTLPNGS-OH
6
H-IGLHAPSHGTLPNGS-OH
7
H-IGLHDPSHGTLPAGS-OH
8
H-IGLHAPSHGTLPAGS-OH
9
H-IGLHDPSHGTLPAGSK-OH
10
H-IGLHDPSHGTLP(Aib)GS-OH
11
H-IGLHDPSHGTLP(N-methyl-L-
Alanine)GS-OH
12
Ac-IGLHDPSHGTLPAGS-OH
13
H-(D-Isoleucine)GLHDPSHGTLPAGS-OH
14
H-(L-NorValine)GLHDPSHGTLPAGS-OH
15
H-(L-NorLeucine)GLHDPSHGTLPAGS-OH
16
Ac-IGLHDPSHGTLPNGS-OH
17
H-(D-Isoleucine)GLHDPSHGTLPNGS-OH
18
H-IGLHDPSHGTEPNGS-OH
19
H-IGLHDPSQGTLPNGS-OH
20
H-IGLHDPTHGTLPNGS-OH
21
H-IGLHDPSHGTLPNGE-OH
22
H-IGLHDPSHGTLPNGK-OH
23
H-IGLHDPSHGTLPAGK-OH
24
H-IGLHDPSHGTEPAGS-OH
25
H-IGLHDPSQGTLPAGS-OH
26
H-IGLHDPTHGTLPAGS-OH
27
H-IGLHDPSHGTLPAGE-OH
28
H-IGLHDPSHGTLPAG-NH2
29
Ac-IGLHDPSHGTLPAGS-NH2
30
Ac-IGLHDPSHGTLPAG-NH2
31
Ac-IGLHDPSHGTLPNGS-NH2
32
H-IGLHDPSHGTLPNGS-NH2
33
H-IGLHDPSHGTLPNGSC-OH
34
Ac-IGLHDPSHGTLPNGSC-OH
35
H-IGLHDPSHGTLPNGSC-NH2
36
Ac-IGLHDPSHGTLPNGSC-NH2
37
H-IGLHDPSHGTLPNGC-OH
38
Ac-IGLHDPSHGTLPNGC-OH
39
H-IGLHDPSHGTLPNGC-NH2
40
Ac-IGLHDPSHGTLPNGC-NH2
41
H-IGLHDPSHGTLPAGS-NH2
42
H-IGLHDPSHGTLPAGSC-OH
43
Ac-IGLHDPSHGTLPAGSC-OH
44
H-IGLHDPSHGTLPAGSC-NH2
45
Ac-IGLHDPSHGTLPAGSC-NH2
46
H-IGLHDPSHGTLPAGC-OH
47
Ac-IGLHDPSHGTLPAGC-OH
48
H-IGLHDPSHGTLPAGC-NH2
49
Ac-IGLHDPSHGTLPAGC-NH2
73
IGLHDPSHGTLPAG
74
IGLHDPSHGTLPNG
75
Ac-IGLHDPSHGTLPNG
76
IGLHDPSHGTLPNG-NH2
77
Ac-IGLHDPSHGTLPNG-NH2
78
H-IGLHDPSHGTLPQGS-OH
79
H-IGLHDPSHGTLPDGS-OH
80
H-IGLHDPSHGTLPEGS-OH
81
H-IGLHEPSHGTLPNGS-OH
82
H-IGLHQPSHGTLPNGS-OH
83
H-IGLHNPSHGTLPNGS-OH
84
H-IGLHEPSHGTLPAGS-OH
85
H-IGLHQPSHGTLPAGS-OH
86
H-IGLHNPSHGTLPAGS-OH
87
H-IGLHDPSHGTLPQGSC-OH
88
H-IGLHDPSHGTLPDGSC-OH
89
H-IGLHDPSHGTLPEGSC-OH
90
H-IGLHEPSHGTLPNGSC-OH
91
H-IGLHQPSHGTLPNGSC-OH
92
H-IGLHNPSHGTLPNGSC-OH
93
H-IGLHDPSHGTLPQG-OH
94
H-IGLHDPSHGTLPDG-OH
95
H-IGLHDPSHGTLPEG-OH
96
H-IGLHEPSHGTLPNG-OH
97
H-IGLHQPSHGTLPNG-OH
98
H-IGLHNPSHGTLPNG-OH
99
H-IGLHEPSHGTLPAG-OH
100
H-IGLHQPSHGTLPAG-OH
101
H-IGLHNPSHGTLPAG-OH
102
H-IGLHDPSHGTLPQGE-OH
103
H-IGLHDPSHGTLPDGE-OH
104
H-IGLHDPSHGTLPEGE-OH
105
H-IGLHEPSHGTLPNGE-OH
106
H-IGLHQPSHGTLPNGE-OH
107
H-IGLHNPSHGTLPNGE-OH
108
H-IGLHEPSHGTLPAGE-OH
109
H-IGLHQPSHGTLPAGE-OH
110
H-IGLHNPSHGTLPAGE-OH.

165 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/094,881Filed 11 May 2017
Published: US 2019/0216883 A118 Jul 2019
Granted: 15 Sep 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 38/10
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 12 to 20 amino acids
A61P 1/18
Drugs for disorders of the alimentary tract or the digestive system: for pancreatic disorders, e.g. pancreatic enzymes
C07K 14/4733
Not used: acute pancreatitis-associated protein
A61K
Medicines and medical preparations

Family

US 2019/0216883 A1Pre-grant publication · published 18 Jul 2019
US 10,772,929 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

A method for treating acute pancreatitis comprising administering to a patient having acute pancreatitis a pharmaceutical composition comprising an INGAP-PP peptide selected from:

TABLE 2
1
H-IGLHDPSHGTLPNGS-OH
6
H-IGLHAPSHGTLPNGS-OH
7
H-IGLHDPSHGTLPAGS-OH
8
H-IGLHAPSHGTLPAGS-OH
9
H-IGLHDPSHGTLPAGSK-OH
10
H-IGLHDPSHGTLP(Aib)GS-OH
11
H-IGLHDPSHGTLP(N-methyl-L-
Alanine)GS-OH
12
Ac-IGLHDPSHGTLPAGS-OH
13
H-(D-Isoleucine)GLHDPSHGTLPAGS-OH
14
H-(L-NorValine)GLHDPSHGTLPAGS-OH
15
H-(L-NorLeucine)GLHDPSHGTLPAGS-OH
16
Ac-IGLHDPSHGTLPNGS-OH
17
H-(D-Isoleucine)GLHDPSHGTLPNGS-OH
18
H-IGLHDPSHGTEPNGS-OH
19
H-IGLHDPSQGTLPNGS-OH
20
H-IGLHDPTHGTLPNGS-OH
21
H-IGLHDPSHGTLPNGE-OH
22
H-IGLHDPSHGTLPNGK-OH
23
H-IGLHDPSHGTLPAGK-OH
24
H-IGLHDPSHGTEPAGS-OH
25
H-IGLHDPSQGTLPAGS-OH
26
H-IGLHDPTHGTLPAGS-OH
27
H-IGLHDPSHGTLPAGE-OH
28
H-IGLHDPSHGTLPAG-NH2
29
Ac-IGLHDPSHGTLPAGS-NH2
30
Ac-IGLHDPSHGTLPAG-NH2
31
Ac-IGLHDPSHGTLPNGS-NH2
32
H-IGLHDPSHGTLPNGS-NH2
33
H-IGLHDPSHGTLPNGSC-OH
34
Ac-IGLHDPSHGTLPNGSC-OH
35
H-IGLHDPSHGTLPNGSC-NH2
36
Ac-IGLHDPSHGTLPNGSC-NH2
37
H-IGLHDPSHGTLPNGC-OH
38
Ac-IGLHDPSHGTLPNGC-OH
39
H-IGLHDPSHGTLPNGC-NH2
40
Ac-IGLHDPSHGTLPNGC-NH2
41
H-IGLHDPSHGTLPAGS-NH2
42
H-IGLHDPSHGTLPAGSC-OH
43
Ac-IGLHDPSHGTLPAGSC-OH
44
H-IGLHDPSHGTLPAGSC-NH2
45
Ac-IGLHDPSHGTLPAGSC-NH2
46
H-IGLHDPSHGTLPAGC-OH
47
Ac-IGLHDPSHGTLPAGC-OH
48
H-IGLHDPSHGTLPAGC-NH2
49
Ac-IGLHDPSHGTLPAGC-NH2
73
IGLHDPSHGTLPAG
74
IGLHDPSHGTLPNG
75
Ac-IGLHDPSHGTLPNG
76
IGLHDPSHGTLPNG-NH2
77
Ac-IGLHDPSHGTLPNG-NH2
78
H-IGLHDPSHGTLPQGS-OH
79
H-IGLHDPSHGTLPDGS-OH
80
H-IGLHDPSHGTLPEGS-OH
81
H-IGLHEPSHGTLPNGS-OH
82
H-IGLHQPSHGTLPNGS-OH
83
H-IGLHNPSHGTLPNGS-OH
84
H-IGLHEPSHGTLPAGS-OH
85
H-IGLHQPSHGTLPAGS-OH
86
H-IGLHNPSHGTLPAGS-OH
87
H-IGLHDPSHGTLPQGSC-OH
88
H-IGLHDPSHGTLPDGSC-OH
89
H-IGLHDPSHGTLPEGSC-OH
90
H-IGLHEPSHGTLPNGSC-OH
91
H-IGLHQPSHGTLPNGSC-OH
92
H-IGLHNPSHGTLPNGSC-OH
93
H-IGLHDPSHGTLPQG-OH
94
H-IGLHDPSHGTLPDG-OH
95
H-IGLHDPSHGTLPEG-OH
96
H-IGLHEPSHGTLPNG-OH
97
H-IGLHQPSHGTLPNG-OH
98
H-IGLHNPSHGTLPNG-OH
99
H-IGLHEPSHGTLPAG-OH
100
H-IGLHQPSHGTLPAG-OH
101
H-IGLHNPSHGTLPAG-OH
102
H-IGLHDPSHGTLPQGE-OH
103
H-IGLHDPSHGTLPDGE-OH
104
H-IGLHDPSHGTLPEGE-OH
105
H-IGLHEPSHGTLPNGE-OH
106
H-IGLHQPSHGTLPNGE-OH
107
H-IGLHNPSHGTLPNGE-OH
108
H-IGLHEPSHGTLPAGE-OH
109
H-IGLHQPSHGTLPAGE-OH
110
H-IGLHNPSHGTLPAGE-OH.

165 more elements

Facts

Application

16/094,881Filed 11 May 2017

Published

US 2019/0216883 A118 Jul 2019

Granted

15 Sep 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 38/10
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 12 to 20 amino acids
A61P 1/18
Drugs for disorders of the alimentary tract or the digestive system: for pancreatic disorders, e.g. pancreatic enzymes
C07K 14/4733
Not used: acute pancreatitis-associated protein
A61K
Medicines and medical preparations